Brian I. Rini

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma

  European Urology · 2026-04-01 · 1 citations

• Abstract A034: HIF-2-mediated gene expression is highest in metastatic and cluster-exclude clear cell renal cell carcinoma tumors

  Cancer Research · 2026-03-13

• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0

  Journal for ImmunoTherapy of Cancer · 2026-03-01 · 1 citations

• Use of ultra-sensitive whole genome circulating tumor DNA detection to predict early recurrence in high-risk localized RCC after nephrectomy: Preliminary real-world findings.

  Journal of Clinical Oncology · 2026-03-01

• Activity and biomarker analyses with casdatifan (cas), a next-generation HIF-2α inhibitor, in refractory clear cell renal cell carcinoma (ccRCC): Results from ARC-20.

  Journal of Clinical Oncology · 2026-03-01 · 1 citations

• Artificial intelligence (AI) as a practical decision support tool for oncologists: Genitourinary (GU) cancer cases.

  Journal of Clinical Oncology · 2026-03-01 · 1 citations

• Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.

  Journal of Clinical Oncology · 2026-03-01

• Phase 1b/2 KEYMAKER-U03 substudy 03C of belzutifan plus zanzalintinib or belzutifan monotherapy for recurrent clear cell renal cell carcinoma during or after anti–PD-(L)1 therapy.

  Journal of Clinical Oncology · 2026-03-01

• A randomized phase 2 trial of nivolumab, relatlimab plus ipilimumab vs. nivolumab plus ipilimumab in first-line advanced renal cell carcinoma.

  Journal of Clinical Oncology · 2026-03-01

• Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization

  Nature Reviews Clinical Oncology · 2026-02-18

• Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

  UNC Libraries · 2025-12-19

• Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

  CA A Cancer Journal for Clinicians · 2025-12-13

• Abstract A023: Erythropoietin (EPO) is a Pharmacodynamic Biomarker for Systemic HIF-2α Inhibition that Correlates with the Clinical Activity of Casdatifan

  Molecular Cancer Therapeutics · 2025-10-22 · 1 citations

• 13Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of belzutifan versus everolimus in previously treated advanced renal cell carcinoma (RCC): LITESPARK-005 (LS-005)

  The Oncologist · 2025-10-01

• 11Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis

  The Oncologist · 2025-10-01

• 44Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC)

  The Oncologist · 2025-10-01

• Long-term Safety and Efficacy of Belzutifan in Von Hippel–Lindau Syndrome: A VHL Coordinating Care Center Experience

  Journal of Kidney Cancer and VHL · 2025-09-05

• 2596MO Phase Ib/II trial of ipilimumab, nivolumab, and ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma (RCC), a kidney cancer research consortium study

  Annals of Oncology · 2025-09-01 · 2 citations

• 2607P Belzutifan for advanced clear cell renal cell carcinoma (ccRCC) after a PD-(L)1 inhibitor and ≥2 VEGFR-TKIs in LITESPARK-005

  Annals of Oncology · 2025-09-01

• 2591O Efficacy of cabozantinib and nivolumab in cluster 1/2 metastatic clear cell renal cell carcinoma: Results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker

  Annals of Oncology · 2025-09-01 · 7 citations